NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Forecast, Price & News

$6.80

+0.30 (+4.62%)

(As of 09/22/2023 08:51 PM ET)

Compare

Today's Range: $6.50
▼
$7.00
50-Day Range: $6.15
▼
$7.77
52-Week Range: $2.11
▼
$13.17

Volume: 8,600 shs
Average Volume: 178,471 shs
Market Capitalization: $30.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.50

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 83.8% Upside
$12.50 Price Target
Short Interest: Healthy
1.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: -0.25
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($11.52) to ($10.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

323rd out of 962 stocks

Pharmaceutical Preparations Industry

140th out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
Corbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.50, Corbus Pharmaceuticals has a forecasted upside of 83.8% from its current price of $6.80.
Amount of Analyst Coverage
Corbus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.71% of the float of Corbus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Corbus Pharmaceuticals has recently decreased by 6.10%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Corbus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corbus Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Corbus Pharmaceuticals is -0.65.

1.0

News and Social Media Coverage

News Sentiment
Corbus Pharmaceuticals has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Corbus Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Corbus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 16.73% of the stock of Corbus Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($11.52) to ($10.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corbus Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corbus Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corbus Pharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Price History

30 days | 90 days | 365 days | Advanced Chart

CRBP Stock News Headlines

September 21, 2023 | americanbankingnews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by StockNews.com to "Hold"

September 19, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 25, 2023 | Stansberry Research (Ad)

1907, 1929, 1998, 2007--and now 2023?

Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.

September 13, 2023 | thestreet.com

Corbus Pharmaceuticals (CRBP) Stock Spikes on FDA Fast Track Status Designation

September 10, 2023 | uk.finance.yahoo.com

CRBP - Corbus Pharmaceuticals Holdings, Inc.

August 9, 2023 | msn.com

Oppenheimer Reiterates Corbus Pharmaceuticals Holdings (CRBP) Outperform Recommendation

August 8, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 31, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

September 25, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

June 26, 2023 | seekingalpha.com

Corbus Pharmaceuticals to join Russell Microcap index

June 26, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Set to Join Russell Microcap® Index

May 31, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

May 23, 2023 | fool.com

Corbus Pharmaceuticals (NASDAQ: CRBP)

May 9, 2023 | msn.com

Recap: Corbus Pharmaceuticals Q1 Earnings

May 8, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

May 5, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms market

May 4, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains

May 2, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock falls Tuesday, underperforms market

May 1, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting

April 25, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors

April 18, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target

March 14, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting

March 13, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock rises Monday, outperforms market

March 7, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update

March 6, 2023 | finance.yahoo.com

Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

March 2, 2023 | finance.yahoo.com

Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 1, 2023 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors

See More Headlines

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings: 8/08/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRBP
CUSIP: N/A
CIK: 1595097
Web: www.corbuspharma.com
Phone: (617) 963-0100
Fax: 617-663-6085
Employees: 33
Year Founded: 2009

Price Target and Rating

Average Stock Price Forecast: $12.50
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +83.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.0021)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -183.08%
Return on Assets: -78.45%

Debt

Debt-to-Equity Ratio: 1.19
Current Ratio: 2.34
Quick Ratio: 2.34

Sales & Book Value

Annual Sales: $880,000.00
Price / Sales: 34.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.91 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 4,420,000
Free Float: 4,123,000
Market Cap: $30.06 million
Optionable: Optionable
Beta: 2.29

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Yuval Cohen Ph.D. (Age 48)
CEO & Director
Comp: $890.67k

Mr. Sean F. Moran CPA (Age 65)
M.B.A., CPA, MBA, Chief Financial Officer
Comp: $579.05k

Dr. Rachael Brake Ph.D. (Age 51)
Chief Scientific Officer
Comp: $552.22k

Ted Jenkins
Sr. Director of Investor Relations & Corp. Communications

Ms. Lindsey Smith
Head of Corp. Communications & Patient Advocacy

Ms. Christina Bertsch
Head of HR

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CRBP Stock - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings or view top-rated stocks.
What is Corbus Pharmaceuticals' stock price forecast for 2023?: 2 brokers have issued 1-year target prices for Corbus Pharmaceuticals' shares. Their CRBP share price forecasts range from $3.00 to $22.00. On average, they anticipate the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 83.8% from the stock's current price.
View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts.
How have CRBP shares performed in 2023?: Corbus Pharmaceuticals' stock was trading at $0.1105 on January 1st, 2023. Since then, CRBP stock has increased by 6,053.8% and is now trading at $6.80.
View the best growth stocks for 2023 here.
Are investors shorting Corbus Pharmaceuticals?: Corbus Pharmaceuticals saw a decrease in short interest in August. As of August 31st, there was short interest totaling 75,400 shares, a decrease of 6.1% from the August 15th total of 80,300 shares. Based on an average trading volume of 14,600 shares, the days-to-cover ratio is currently 5.2 days. Approximately 1.7% of the company's stock are short sold.
View Corbus Pharmaceuticals' Short Interest.
When is Corbus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CRBP earnings forecast.
How were Corbus Pharmaceuticals' earnings last quarter?: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($2.05) EPS for the quarter, topping the consensus estimate of ($3.10) by $1.05.

What other stocks do shareholders of Corbus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).
What is Corbus Pharmaceuticals' stock symbol?: Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
Who are Corbus Pharmaceuticals' major shareholders?: Corbus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.85%) and Dimensional Fund Advisors LP (0.72%). Insiders that own company stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends.
How do I buy shares of Corbus Pharmaceuticals?: Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Corbus Pharmaceuticals' stock price today?: One share of CRBP stock can currently be purchased for approximately $6.80.
How much money does Corbus Pharmaceuticals make?: Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $30.06 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($11.0021) on an earnings per share basis.
How can I contact Corbus Pharmaceuticals?: Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial